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Abstract

Background/Purpose: GATA2 and Dedicator-of-Cytokinesis-8 (DOCK8) deficiencies are two
recently described genetic immunodeficiency diseases for which allogeneic hematopoietic stem
cell transplant (HSCT) represents the only definitive therapy. The patient characteristics and
HSCT variables that relate to the outcomes in these two diseases following HSCT remain
unclear. Therefore, we described these variables in these two patient populations and explored
their relationships with HSCT outcomes.
Methods: Data were obtained from retrospective chart reviews of all patients with GATA2
deficiency and DOCK8 deficiency who underwent HSCT on clinical research protocols at the
National Cancer Institute. The outcomes included overall and disease-free survival status, graftversus-host disease (GVHD), and HSCT complications.
Results: Of the 51 patients who underwent HSCT, 37 had GATA2 deficiency and 24 had
DOCK8 deficiency. On the GATA2 protocols, 28 of 37 patients (75%) were alive at the time of
the review and all had reversal of the disease phenotype. GATA2 deficiency patients had a mean
of 2.2 (SD=1.2) and 0.8 (SD=1.1) life-threatening infections pre-HSCT and post-HSCT,
respectively. Of the 24 DOCK8 patients on protocol 19 (79.2%) were alive at the time of review
and all had correction of their underlying disease. The DOCK8 patients had a mean of 1.8
(SD=0.7), and 0.9 (SD=0.7) life-threatening infections pre-HSCT and post-HSCT, respectively.
Conclusions & Implications: This study fills a gap in the scientific literature by providing data
on patient characteristics, HSCT factors, treatment access, and the clinical outcomes for two the
recently described primary genetic immunodeficiency diseases. Our results indicate that patients,
with GATA2 or DOCK8 deficiencies undergoing HSCT prior to the development of lifethreatening infections, end-organ damage, or myeloid transformation, have favorable clinical
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outcomes with correction of the underlying immunodeficiency. This study provides information
for health care providers caring for these patients, on the effect of the social determinants and
prognostic factors on successful HSCT.

Keywords: GATA2 deficiency, Dedicator-of-Cytokinesis-8 (DOCK8) deficiency, allogeneic
hematopoietic stem cell transplant (HSCT)
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Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 and DOCK8
Immundeficiencies: Demographics and Transplantation Variables
Primary immunodeficiency diseases (PID) are a collection of more than 300 genetic
disorders that result in a variety of defectively functioning immune systems, resulting in an
increased risk of life-threatening infections in affected patients. Infections may involve the skin,
sinuses, throat, ears, lungs, brain, urinary, intestinal tract, and spinal cord. These infections are
recurrent and severe, and frequently do not respond to treatment. Patients with PIDs suffer
recurrent hospitalizations for these serious, life-threatening illnesses (Immune Deficiency
Foundation, 2018). While many PIDs have an identified genetic link, others do not; these
diseases were commonly lumped together as common variable immunodeficiency or severe
combined immunodeficiency disease. With the increasing use of newborn screening and whole
exome sequencing, these diseases are now recognized earlier and differentiated into specific
subtypes, facilitating more targeted therapies.
Allogeneic hematopoietic stem cell (HSCT) has been used as a therapy for PID for nearly
50 years. In this project HSCT was used to treat two newly recognized PID entities, GATA2
deficiency (Spinner et al., 2014) and Dedicator-of-Cytokinesis-8 (DOCK8) deficiency (Zhang et
al., 2009). Patient demographics and transplant variables, and their relationships with post-HSCT
outcomes, are examined.
Background of Research
Clinical research trials (protocols) for HSCT at the National Institutes of Health (NIH),
National Cancer Institute (NCI) in Bethesda, Maryland have been used to treat patients with
GATA2 and DOCK8 deficiency for the preceding decade. Two sequential HSCT protocols were
used for GATA2 deficiency. The first protocol, a low-intensity regimen was entitled: Pilot and
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Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC (09C-0096/NCT00923364). The subsequent protocol utilized a higher intensity, chemotherapybased regimen and was entitled: Allogeneic Hematopoietic Stem Cell Transplant for Patients
with Mutations in GATA2 or the MonoMAC syndrome (13-C-0132/NCT01861106). The DOCK8
protocol was entitled: Related and Unrelated Donor Hematopoietic Stem Cell Transplant for
DOCK8 Deficiency (10-C-0174/NCT01176006). In addition to being PIDs, both GATA2
deficiency and DOCK8 deficiency are also cancer predisposition syndromes, either from viraldriven malignancies, or in the case of GATA2 deficiency, from myeloid malignancies. The
principal investigators for these trials are in the NCI. The studies were carried out in the Clinical
Research Center at the NIH campus.
Transplantation for PIDs
The use of HSCT originated more than 50 years ago. HSCT was originally designed as a
treatment for injury from accidental radiation injury. HSCT was later developed as a treatment
for leukemia and other diseases. HSCT is increasingly being used to treat both malignant and
nonmalignant conditions (Copelan, 2006). Allogeneic (related or unrelated donor) HSCT has
been used for nearly 50 years for the treatment and cure of PID. Studies have shown that the
future improvements in the treatment of PIDs with HSCT are possible only with an increased
knowledge and understanding of genetics and immunobiology, including matching of donors,
decreasing the toxicity of the conditioning regimens, and preventing GVHD (Worth, Booth, &
Veys, 2013).
There have been rapid advances in the identification of the genetic defects resulting in the
ability to identify affected individuals, and the identification of families that carry the genetic
traits (Al-Herz et al., 2014). However, due to the limited scope of HSCT treatment in GATA2
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and DOCK8 deficiencies, patient demographic, transplantation characteristics, and past medical
history and allogeneic HSCT have not been previously reported in patients who underwent
HSCT for GATA2 or DOCK8.
GATA2
GATA2 deficiency was first described by four different research groups resulting in four
different names: 1) monocytopenia and mycobacterial infections or MonoMAC; 2) deficiencies
in dendritic, monocyte B, and natural killer lymphoid cells; 3) familial myelodysplastic
syndrome (MDS)/acute myeloid leukemia (AML); 4) Emberger syndrome (Spinner et al., 2014).
Individuals with GATA2 deficiency suffer from severe, life-threatening infections, respiratory
problems, deafness, lymphedema, and leukemia. Signs and symptoms of GATA2 deficiency first
appear in childhood or early adulthood.
Allogeneic HSCT represents the only definitive therapy for GATA2 deficiency. HSCT
replaces the defective immune cells in the patient with GATA2 deficiency with those from a
healthy donor (National Institutes of Allergy and Infectious Diseases [NIAID], 2016). GATA2
deficiency is familial in approximately 50% of patients with the disease (Vinh et al., 2010). The
GATA2 mutation in the familial cases are inherited as Mendelian dominant, resulting in loss of
activity, or haploinusufficiency. The other 50% of patients have a de novo mutation; with no
other members of the family harbor the GATA2 mutation. It is important to note that the
majority (72%) of adolescents with MDS and monosomy 7 (a single copy of chromosome 7),
will have an underlying GATA2 deficiency (Wlodarski et al., 2016). See Figure 1, Clinical
Features of GATA2.
The syndrome of monocytopenia and mycobacterial infections, typically Mycobacterium
avium, termed “MonoMAC,” was first recognized at the NIH, (Hsu et al., 2011). Prior to
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GATA2 deficiency being genetically identified, patients were diagnosed as having the
MonoMAC syndrome. Both GATA2 protocols at the NCI, allowed patients without an identified
mutation of GATA2 to be enrolled on protocol and transplanted under the phenotypic diagnosis
of the MonoMAC syndrome. These patients are thought to have mutations in regulatory
sequences that control the expression of GATA2.
The alterative option for patients with GATA2 includes not undergoing HSCT, and
instead receiving supportive care therapies for the complications due to their GATA2
deficiencies (cancer surveillance, viral or bacterial infections) (Cuellar-Rodriguez et al., 2011).
Although healthy at childhood, patients with GATA2 have a 90% risk of clinical complications,
including MDS by the age of 60 (Spinner et al., 2014). GATA2 patients have a median survival
of 60 years (Collin, Dickinson, & Bigley, 2015). Six patients with GATA2 deficiency who were
seen at the NIH and did not undergo HSCT – either due to lack of donors or personal choicesubsequently died from complications of the disease, usually infection or cancer. Given the lethal
outcome of untreated GATA2 deficiency, currently the only option for a cure and a disease-free
survival is the reconstruction of the hematopoietic compartments using allogeneic HSCT
(Cuellar-Rodriguez et al., 2011).
GATA2 is a gene that encodes a member of the GATA family of zinc-finger transcription
factors and is relatively a rare genetic disease. The GATA2 protein has the key function in the
regulation of gene transcription for hematopoietic cell lineage development and proliferation. As
a master regulator of hundreds of genes, GATA2 deficiency results in a constellation of disease
manifestations (Genetic Home Reference, 2018). Wlodarski, Collin and Horwitz (2017) report
that the loss of function of GATA2 will lead to aberrant hematopoiesis with myeloid neoplasia,
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that can be diagnosed by acquisition of abnormal cytogenetic results. Kiraly et al. (2017) reports
that in familial MDS/AML, there may other genetic diseases than GATA2 deficiency.
Spinner et al., (2014) examined 57 patients with GATA2 deficiency: 40 of these patients
presented with clinical evidence of disease, and 17 were identified by family screening. They
found that 50% of the patients had symptoms by age 20. The ethnicities in this study indicated
that: 75% were white, 16% were Hispanic, 7% were African American, 2% were Asian, and
54% were female. The median age for the patient’s first visit was 30 years old, with an age range
of 4 to 76 years. Ninety-three percent of patients had a history of at least one of the following
clinical manifestations: several viral infections or nontuberculous-mycobacteria infection,
MDS/AML, pulmonary alveolar proteinosis, or lymphedema. Spinner et al., (2014) found the
following complications in the patients: 32% severe viral infections, 21% MDS/AML, 9%
lymphedema, and 4% invasive fungal infections. The survival of patients declined to 91% by 5year post onset, 84% at 10 years, and 67% at 20 years. Of the 57 patients, 21 of the patients
underwent HSCT with an age range from 15-49. Only one publication, Spinner et al., (2014), has
discussed patient demographic and medical history. However, more extensive information from
a much larger cohort is now available, and this data forms the basis for part of this study.
Ramzan et al. (2017) describes the youngest pediatric case of 4.5-year-old girl with GATA2, and
Emberger syndrome in a case report.
Dedicator-of-cytokinesis-8
Dedicator-of-cytokinesis-8 (DOCK8) deficiency was initially termed an autosomal
recessive hyper IgE syndrome prior to identification of the gene defect in 2009; it is caused by a
rare, autosomal recessive inherited mutation (Zhang et al., 2009). DOCK8 deficiency can cause
dysfunction of the immune system, resulting in recurrent, chronic, and debilitating infections
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(NIAID, 2017). Patients have persistent skin infections caused by different deoxyribonucleic
acid (DNA) viruses including: herpes simplex virus (HSV) (cold sores), human papillomavirus
(HPV) (warts), Herpes varicella-zoster virus (VZV) (shingles), and Epstein Barr Virus (EBV)
infections. Additionally, DOCK8 patients frequently have severe allergies, eczema, and asthma.
They are at increased risk for developing cancers (HPV-driven) squamous cell carcinoma and
(EBV-driven) lymphoma. Treatments for DOCK8 deficiency include supportive care such as
prolonged use of antibiotics and antibody therapies (NIAID, 2017). See Figure 2, Clinical
Features of DOCK8. Due to the combined immunodeficiency, the recommended treatment of
patients with DOCK8 deficiency is HSCT (NIAID, 2017). Given the autosomal recessive
inheritance pattern, consanguinity is frequently seen in families with DOCK8 (CuellarRodriguez et al., 2015).
The prognosis for untreated patients with DOCK8 is poor; by the age of 20 the overall
survival of patients is only 47%. Life-threatening complications of the disease include severe
infections, malignancies, and central nervous systems vasculitis. The first reports of successful
HSCT treatment for DOCK8 patients indicated the promise of this treatment (Gatz et al., 2011).
This publication contained limited patient demographic and medical history data. Al-Herz et al.
(2016) reported that the use of HSCT as a curative therapy and recommended this treatment for
patients, given the high morbidity and mortality associated with DOCK8 deficiency. Since then
the use of HSCT has been associated with successfully immune reconstitution and reversal of
infectious complications.
Specific Aims
The aim of this study was to document patient’s demographic information,
transplantation characteristics, past medical history, disease-free survival, and post-transplant
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complications at one-year post transplant in patients with GATA2 deficiency and DOCK8
deficiency who received HSCT.
Research Question
There are two research questions. First, what are the demographics, transplantation
characteristics, and past medical history of patients with GATA2 and DOCK8
immunodeficiencies treated with HSCT? Second, do these variables relate to post-HSCT
complications and one-year disease-free survival?
Purpose
Study Variables (Outcome Measure of Interest)
The following outcome areas of interest for transplant outcomes were examined: (a)
disease-free survival (engraftment and chimerism); and (b) post-transplant complications (lifethreatening infections, graft versus host disease (GVHD), and death). See Table 1, Study
Variables (Outcome Measure of Interest).
Demographic and Clinical Variables
The following variables were examined: (a) patient’s demographic information, (b)
transplant characteristics, and (c) past medical history. The patient’s demographic information
includes: (a) insurance status, (b) caregiver status, (c) gender, (d) occupation/employment, (e)
documentation/immigration status, (f) baseline performance status score (adults: Karnofsky,
pediatrics: Lansky), (g) race, (h) ethnicity, (i) marital status, (j) illicit drug history, and (k) access
to care primary care provider). Transplant characteristics include: (a) graft source, (b) donor sex,
(c) donor age, (d) conditioning chemotherapy regimen, (e) donor source, (f) graft match, (g)
blood type (donor/recipient), and (h) viral status including Cytomegalovirus (CMV) and EBV
(recipient/donor). Past medical history includes: (a) diagnosis, (b) mutation type, (c) identified
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mutation, (d) cancer/hematological diagnosis, (e) baseline bone marrow cytogenetics, (f) familiar
component, (g) age of diagnosis, (h) age at transplant, (i) number of life-threatening infections
(pre-HSCT), and (j) serious lung infection. It was important to research these variables to
understand trends and differences in post-transplant outcomes, and to identify characteristics of
patients with post-transplant complications. The conclusions of this study will assist researchers
and health-care providers to prepare, anticipate, and plan the optimal timing of HSCT to
optimize patient outcomes. See Table 2, 3, and 4 Demographic and Clinical Variables.
Significance
The retrospective chart review was conducted utilizing three clinical research protocols at
the NCI. The NCI has the largest collection of data in the world on GATA2 deficiency and
DOCK8 deficiency patients who have undergone HSCT since both diseases were identified at
the NIH. The NIH was one of the first centers to initiate prospective HSCT for these two
diseases. Many of the patients that undergo HSCT at NCI, and their family members (given the
large genetic component of these diseases) have been patients at the NIH for many years. The
researchers at the NIH are interested in determining and evaluating the efficacy, safety and posttransplant complications of HSCT. Allogeneic HSCT is a potentially life-saving treatment for
patients with PID, however, the treatment is not a risk-free therapy, and very little research has
evaluated the effect of patient demographics on the post-transplant outcomes in these patients.
Patient demographics can be associated with both optimal outcomes and poor outcomes,
increased knowledge will help providers to manage these patients effectively.
Given the rareness of these diseases, nurses in general have limited information about the
patient characteristics, treatment options, outcomes, and follow-up care following HSCT. This
study will provide data so that nursing and other health care professionals can design effective
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care plans for these patients and their families. Oncology nurses play a critical role in caring for
these patients, identifying family members at risk, and identifying prognostic factors for HSCT.
The results can help nurses develop better nursing care plans for GATA2 and DOCK8 deficiency
patients who have received HSCT.
Literature Review
A NIH research librarian was consulted on search terms and appropriate databases for the
research question. We have noted that most research articles published on HSCT for DOCK8
and GATA2 deficiency were based on research that was done at the NIH, and/or that NIH
investigators were listed as co-authors. We searched PubMed and MEDLINE using MeSH terms
and key words such as “transplant*” “transplants,” and “transplantation.” We used the Boolean
connector AND to link population and intervention key words, for example, GATA2 AND stem
cell transplant.
Because transplantation for both diseases is relatively new, there were limited amounts of
research articles available. Additionally, limited information was available on the demographic,
past-medical history, and transplantation characteristic for patients with DOCK8 and GATA2
deficiency. Therefore, this project will help remedy deficiencies in the literature.
Transplantation for GATA2
Cuellar-Rodriguez et al. (2011) described the background and foundation for HSCT in
patients with GATA2 deficiency. The outcomes, of the first six patients with the newly described
genetic syndrome GATA2 who had undergone transplantation at the NCI, were reported.
Engraftment of donor cells, percent of donor chimerism, and cytogenetics (chromosomal
abnormalities) were examined pre-transplant and at post-transplant time points. Examination of
post-transplant complications were discussed, including complications of GVHD and infections.
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At a median follow-up of 17.4 months, 5 of the 6 patients were alive, and all had achieved high
levels of donor engraftment. Post-transplant complications consisted of delayed engraftment,
GVHD in four patients, and immune-related pancytopenia and nephrotic syndrome in one
patient.
A follow-up report from the NIH described a total of 14 patients with GATA2 deficiency
who received a nonmyeloablative allogeneic HSCT (Grossman et al., 2014). Of the 14 patients
transplanted, four different donor sources were utilized: 4 patients received peripheral blood
stem cells from matched related donors, 4 patients received peripheral blood stem cells from
unmatched related donors, 2 patients received bone marrow cells from haploidentical related
donors, and 4 received hematopoietic stem cells from umbilical cord blood donors. Conditioning
regimens and post-transplant immunosuppression therapies were based on the type of donor
graft. Immune reconstitution, cytogenetics, and analysis of chimereism were all examined at
post-transplant time points. Eight of the 14 patients were alive at the time of follow up (median,
3.5 years), with reconstitution of severely deficient monocyte, B cells, and natural killer cell
populations, and reversal of the clinical phenotype. Two patients rejected the donor graft, and
one patient had relapsed with MDS. In neither this study nor the preceding study, were the
implications for nursing care discussed.
Providers caring for bone marrow failure diseases (including GATA2) confront a
challenge in preparing patients for HSCT. Lad et al. (2016) reported that allogeneic HSCT can
offer a long-term solution for GATA2 patients, given their countless number of complications
(marrow failure, immunodeficiency, and pulmonary disease). Additionally, that there can be a
reversal after HSCT of lung pathophysiology abnormalities. Many patients have pre-existing
organ dysfunction which places them a higher risk of complications. There is also the risk for
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morbidity and mortality from the conditioning chemotherapy used to destroy the abnormal
marrow, and to facilitate donor engraftment. These factors justify the need to develop less toxic
myeloablative regimens (Burroughs et al., 2017).
HSCT for familial diseases such as GATA2 deficiency provides the opportunity to carry
out HSCT on more than one family member. Shah et al. (2017) discussed their experience with
transplantation of monozygotic twins with GATA2 who received marrow from the same
haploidentical donor but had different transplantation outcomes in terms of GVHD. This report
demonstrated that variability in outcomes can be expected, depending on prior infectious
exposures.
Transplantation for DOCK8
Cuellar-Rodriguez et al. (2015) described six DOCK8 deficiency patients who underwent
matched related and unrelated donor HSCT at the NCI, and all six patients achieved rapid levels
of donor engraftment and reversal of their DOCK8 clinical and immunologic phenotype. The
authors concluded that with genetic testing for DOCK8 deficiency enabling earlier diagnosis and
HSCT, patients would be expected to be diagnosed earlier and undergo HSCT earlier in their
clinical course with subsequent decrease in organ damage or life-threatening infections.
Additional studies of HSCT for DOCK8 deficiency were reported. Uygun et al. (2017)
transplanted five pediatric patients with DOCK8 with unrelated donors. All patients successfully
recovered from allogeneic HSCT following myeloablative conditioning chemotherapy, with
reasonable safety profiles. Freeman et al. (2016) from the NIH described the first successful use
of haploidentical HSCT with post-transplant cyclophosphamide to reverse the DOCK8
phenotype. The use of haploidentical donors in this population increases donor availability and
options.
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Patients with DOCK8 are at risk for developing cancers. A secondary diagnosis of cancer
could further justify the treatment decision for HSCT. Dimitriades et al. (2017) discusses a
DOCK8 patient with EBV lympholiferative disease that was still progressing, necessitating the
curative therapy of HSCT. The incidence of malignancy in a patient’s DOCK8 disease can be
beneficial for early diagnosis and HSCT.
Screening and treatment of complications are parts of the complex management of
DOCK8 deficiency, including administration of immunoprophylaxis, and definitive therapy with
HSCT. Patients should be evaluated with viral studies, baseline imagining, identification of
cancers, complications from chronic infections, and assessment of pulmonary, cardiac, and liver
impairments. These findings should all be assessed, treated, and managed aggressively prior to
transplantation (Biggs, Keles, & Chatila, 2017).
Intervention
Stem cell transplant and characteristics. There are usually three different graft/donor
sources that can be used in transplantation: allogeneic (patient receives their cells from a healthy
related or unrelated donor), autologous (patient receives their own cells), or syngeneic (patient
receives cells from a genetically identical twin). However, for DOCK8 and GATA2 transplants,
an autologous and syngeneic graft are not a curative graft source option since a graft source that
does not have the disease is required.
Allografting is a term used to describe transplanting cells to a recipient that is genetically
different. The human leukocyte antigen (HLA) system is used to determine the best possible
match for donor stem cell sources. HLA is a protein marker found on the surface of white blood
cells. Ideally, a patient is transplanted with a donor that matches a 10 out of 10 HLA loci. Half of
HLA markers come from the mother, and the other half from the father. Allografts are done with
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the closest matches, including a family member or an unrelated donor identified from a donor
registry. It is important to note that given the genetic component with GATA2 and DOCK8
deficiency, when searching donor availability amongst family members, the donors must be
screened to ensure they are not affected with either GATA2 or DOCK8. However, since DOCK8
is a recessive disease, such that one would need two abnormal copies of a DOCK8 gene to be
affected, donors who are carriers of a DOCK8 mutation are asymptomatic and can be used as
donors. Matched unrelated donors carry a slightly higher risk because of increased incidence of
GVHD, and delayed immune reconstitution (Wilke Shapiro, 2016).
The sources of allogeneic HSCT products can be either umbilical cord blood (stored at
birth delivery), bone marrow, or peripheral blood stem cells. Depending on donor availability
and health status, the procedure may involve either having a bone marrow harvest procedure
done in the operating room, or from peripheral blood stem cells harvested after receiving
hematopoietic growth factors to mobilize stem cells into the circulating peripheral blood. Bone
marrow cells take longer to engraft, and are associated with a lower incidence of GVHD,
compared to peripheral blood stem cells. Prior to the day of transplant, “conditioning” therapy is
given to allow for the patient’s body to accept the donor cells. The conditioning may consist of
high-dose chemotherapy, total body irradiation, and biological modifiers.
Given the limited understanding of these diseases, they provide unique challenges for the
health providers. Additional manifestations of the disease could be discovered during the
transplant period. The clinical course of underlying disease can significantly improve with
aggressive supportive care. Incomplete knowledge of the nonimmunological and immune
pathophysiology effects of the mutations need to be further studied to determine if HSCT is a
complete cure (Connelly, 2017).
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Patient demographics. Many factors increase the risks of complications occurring
during transplant including: previous cancer therapies, underlying organ disease (lung, liver,
kidney, or cardiac dysfunction), previous infection history, age (older patients have more
transplant related complications), and possible psychological dysfunction. Assessment of the
patient’s caregiver’s ability to implement and care for patient demands is also important.
Community involvement, insurance coverage, employment, and financial resources are an
essential part of a social evaluation (Wilke Shapiro, 2016).
Outcomes
Engraftment. Post-transplant donor chimerisms are monitored. Chimerism is measured
by the percentage of donor cells compared to the recipient’s cells. Chimerism can be monitored
from the bone marrow and/or peripheral blood. Prior to transplant, a sample of the donor’s and
the recipient’s DNA are sent to the lab for analysis and saved for later comparison. Additionally,
other hematological values (complete blood count), minimal disease markers can be used to
evaluate engraftment at specific time points (Wilke Shapiro, 2016).
Post-transplant complications. Monitoring for the immediate post-transplant
complications includes: hepatic sinusoidal obstruction syndrome, GHVD, idiopathic pulmonary
interstitial pneumonitis, and infections (viral or bacterial). Long-term post-transplant
complications include fatigue, weight loss, chronic GVHD, fertility issues, organ dysfunction
(pulmonary, renal, cardiac, adrenal), infection, and psychological disorders (Wilke Shapiro,
2016). Other post-transplant complications can include death, and relapse of disease.
Theoretical Framework
This project was based on the theoretical framework from the World Health Organization
(2010), the social determinants of health. The three main theoretical components within this
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concept are: 1) psychosocial approaches, 2) disease/political economy of health social
production, and 3) eco-social frameworks. All three of these theories follow pathways and
causation mechanisms. The framework examines how social positions can play roles in health
care inequities and outcomes.
The influence of demographic, transplantation characteristics, and past medical history on
HSCT outcomes on DOCK8 and GATA2 patients examines the social determinants of health
conceptual framework and assists in determining an explanation between some of the variables.
The conceptual framework examines structural and intermediary social determinates of health
and inequalities. There are context-specific strategies for tackling both structural and
intermediary determinates. See Figure 3, Theoretical Framework.
Methods
Research Design
This is a retrospective, observational study using previously collected data from patients
who enrolled in three NCI clinical research protocols. There were no interventions in this
retrospective study. However, all patients received a HSCT for GATA2 or DOCK8 deficiency as
part of their treatment in their original clinical research protocols at the NIH.
Study Population/Sample Size
The study participants included patients with a diagnosis of GATA2 or DOCK8
deficiency who were enrolled from 2009 to 2016 in one of the three clinical research protocols at
the NIH. The NCI Principal Investigators, also authors of this study, granted permission to use
the data. The inclusion criteria for this secondary data analysis study included patients who were
enrolled in one of the three clinical research protocols, and who have outcome data available for
at least one-year post-transplant. Those patients less than one-year post-transplant were excluded
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from this study. Both the NCI’s and The George Washington University GWU)’s Institutional
Review Board (IRB) reviewed and approved the research that was conducted in this project (See
Letter 1, Letter from NCI to GWU IRB and Letter 2, GWU IRB Approval).
Due to the limited scope of the patient population and treatment, all cases were who met
the inclusion criteria were reviewed. A total of 39 GATA2 and 24 DOCK8 deficiency patient
charts were included in this study. This sample size is one of the largest, compared to the
literature studies previously described.
Instrumentation/Measurements
All study variables were collected from information extracted in the electronic medical
record (EMR) from social worker notes, information collected from patients (self-reported) in
admissions, and data added by the from research team.
Setting
Patients in this study underwent HSCT treatment while enrolled in clinical research
protocols that were conducted at a single-site facility at the NIH, NCI in Bethesda, Maryland.
Patients were admitted to the Clinical Center, the hospital facility at the NIH campus in
Bethesda. All patients were admitted to the Clinical Center during their transplant and acute
phase post-transplant. The patients remained in the Bethesda area for approximately 100-days
post-transplant and were seen on a bi-weekly basis in the outpatient clinics and day hospital at
the Clinical Center. If patients were not local to the Bethesda area, the patients were then
transitioned to their home medical teams (frequently oncologists, infectious disease specialists,
or hematologists). Patients were expected to return to the Clinical Center for routine and clinical
monitoring, as specified in the protocol. One check point was one-year post transplant.
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Data Collection Procedure and Timeline
Data was obtained from the EMR and from the research protocol database. Data was
organized and collected by putting the data into Excel spread sheets, with secure access. The
NCI’s research protocol database, the Cancer Central Clinical Database (C3D), is used by NCI
staff to examine, analyze and publish.
A NCI data manager were responsible for entering research data into C3D. The research
team was responsible for verifying the data that is entered in C3D from source documents
(EMR). The specific data that was entered in C3D is determined by the research protocol.
Standard case report forms, laboratory, and demographic information and data were entered in
C3D. Members of the research team including principal investigators, research nurses, and data
managers all had research and institution (NCI) specific mandatory training, and good clinical
practice education.
All the stored study research data was assigned a numeric code, of which the research
team has the key. Data was stored on a password-protected secure drive, which had limited
access. Any disbursement of the research data was documented.
The Clinical Center is the Nation’s research hospital. The health care delivery model of
“bench to bedside” is extremely specialized and exceptional. Research conducted at the Clinical
Center must fit within in the legal and regulatory environments required for the governmentsponsored research done at the NIH, including conducting clinical laboratory analysis in clinical
laboratory improvement amendment (CLIA) certified facilities. The data was used in this study
was previously collected by an expert team of researchers at the NIH as part of three NIH
approved protocols. The NIH’s EMR maintains complete records on patients including any
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supplementary information obtained from outside providers. The NCI C3D serves as the primary
source from which the research analyses were conducted, here researchers extract data.
Data was extracted by either automatic electronic extraction from C3D reports, or manual
extraction from C3D or the EMR. The researcher (a NCI senior research nurse specialist)
compiled the data set. The researcher underwent multiple educational and training sessions when
being hired, and as required to maintain annual competency training. The trainings received
include security and privacy awareness, ethics, financial disclosure, equal opportunity
employment, diversity awareness, Clinical Center orientation, EMR, responsible conduct of
research, human subject protection and good clinical practice (Collaborative Institutional
Training Initiative), clinical trials modules and orientation, use of C3D, research protocol review,
and integrated research information system reporting.
The NCI data managers are individuals with a healthcare and/or science background.
Orientation for data mangers consist of overview of cancer and medical terminology, medical
terminology, overview of clinical trials, Collaborative Institutional Training Initiative training,
Clinical Center orientation, C3D, and intermural research program orientation. The data
managers assisted the extraction of data in this project. The timeline from the project was
outlined in Table 5, GANTT Table.
Data Analysis Plan
The statistical Package for the Social Science (SPSS) version 24 was used to analyze the
data (IBM, 2018). Descriptive statistics was reported for the study variables. The means, ranges,
medians, and standard deviations for the continuous variables were calculated along with
frequencies, and percentages for categorical variables. Independent t-test and chi-square test
were considered to explore relationships among variables. For all analyses, alpha was set at 0.05.
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Ethical Considerations

Both men and women, and members of all races or ethnic groups were eligible to
participate in the NIH original research protocols. The data was managed and handled to ensure
patient confidentially and follow institutional guidelines. Data was only collected after approval
was granted by the IRB at both NIH and GWU. All of the study research data were assigned a
numeric code known only by the research team to identify the patients. Data was kept on a
secure drive with limited access only, and password-protected. Any disbursement of the research
data was documented. Confidentially was maintained. The resulting publications from this
project will not contain subject names or any personal identifying information.
Results
Overview
The comprehensive list of variables by disease (GATA2 and DOCK8 deficiency) that
were collected and analyzed are described in the following: Table 6, Descriptive Tables: Medical
Outcomes; Table 7, Descriptive Tables: Demographics; Table 8, Descriptive Tables: Transplant
Characteristics); and Table 9, Descriptive Tables: Medical History. There were 39 patients
enrolled in the GATA2 deficiency protocols for HSCT, and 24 patients in the DOCK8 deficiency
protocol for HSCT. Of the 39 patients enrolled in two GATA2 protocols, 33 patients had a
confirmed GATA2 mutation (84.6%), and 6 patients (15.4%) were enrolled having the
MonoMAC syndrome (with no identified GATA2 mutation). When examining the posttransplant outcomes, one of the GATA2 patients who was enrolled in study was removed from
study prior to transplant (received a transplant on a different protocol), and one patient was
removed from the protocol at approximately day 100 post-HSCT but included in this analysis.
All of the DOCK8 patients had identified DOCK8 mutations.
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Outcomes
At the time of data collection, of the 37 patients that received a HSCT under the GATA2
protocols, 28 (75.7%) were alive. For the living patients, the mean time post-transplant was 46
months (SD=27.7 months) after HSCT. Nine (24.3%) of the GATA2 patients had died (two from
sepsis, one from GVHD, three from graft failure, one from donor cell leukemia, one from cardiac
arrest, and one from malignant disease). For the patients that died, the mean time of death was
349 days (SD=356 days) after HSCT. Nineteen (79.2%) of the 24 DOCK8 patients were alive.
For the surviving patients, the mean time post-transplant was 38 months (SD=17 months) after
HSCT. Five (20.8%) of the patients died (two from infection/graft failure, two from GVHD/graft
failure, and one from an illicit drug overdose). For the patients that died, the mean time of death
was 246 days (SD=342 days) after HSCT.
The average number of life-threatening infections post-HSCT for GATA2 and DOCK8
deficiency patients were 0.8 (SD=1.1) and 0.9 (SD=0.7), respectively. Post-HSCT engraftment
of the GATA2 and DOCK8 patients are 33 (94.3%) and 22 (91.7%), respectively. All of the
patients, living at one-year post-HSCT, had a complete response. Chimerisms at one-year postHSCT for GATA2 were: 97.7% (SD=8%) in the whole blood, 94% (SD=12.8%) in the CD3
lineage, and 98.7% (SD=6.9%) in the myeloid lineage. Chimerisms at one-year post-HSCT for
DOCK8 were: 99.9% (SD=6.3%) in the whole blood, 100% (SD=0%) in the CD3 lineage, and
99.9% (SD=0.5%) in the myeloid lineage.
Acute and/or chronic GVHD are known complications post-HSCT. Many of the patients
experienced (acute and/or chronic) GVHD at some time post-HSCT, affecting a specific organ.
GVHD was a lethal complication in only three patients (two DOCK8 and one GATA2 patients).
GATA2 patients had more GVHD overall, than DOCK8 patients. This explains why more
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GATA2 patients 18 (60%) were on immunosuppression at one year, compared to only 3 (15%)
of DOCK8 patients.
Demographics
The majority of GATA2 deficiency patients (37, 94.9%) had caregivers. All of the 24
DOCK8 patients had caregivers. The percentage of male patients for GATA2 and DOCK8 was
38.5% and 41.7%, respectively. All 24 (100%) of the DOCK8 patients had a caregiver. The
average yearly age at the time of transplant for GATA2 patients was 27 (SD=7.9 years) and
DOCK8 patients was 17.08 (SD=5.7 years). The average baseline performance score (Kanofskyadults, Lansky-pediatrics) at the time of protocol enrollment was 65.5 (SD=22.5) for GATA2
and 80.4 (SD=15.2) for DOCK8 patients. GATA2 patients on average were 10 years older than
DOCK8 patients at the time of transplant. This could explain the higher baseline performance
score in DOCK8 patients in that the DOCK8 patients were younger, and with less comorbidities, causing them to have higher performance scores (15 higher than the GATA2
patients). The DOCK8 patients were identified with problems earlier, and they had a diagnosis
sooner. Given the younger age of patients at the time of transplant, it was confirmed that many of
the GATA2 and DOCK8 patients were students, 28.3% and 83.3%, respectively. The majority of
GATA2 and DOCK8 patients were single, 76.9% and 95.8%, respectively.
Transplant Characteristics
The donor’s average yearly age for GATA2 and the DOCK8 patients was 33 (SD=14.6
years) and 31.3 (SD=13.3 years), respectively. A total of 5 patients received umbilical cord blood
transplants (cord), donor age is not applicable for those cases. Of the 38 GATA2 patients, 6
(15.8%) received a matched-related donor transplant, 18 (47.4%) an unrelated donor transplant,
10 (26.3%) a haploidentical donor transplant, and 4 (10.5%) an umbilical cord blood transplant.
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Of the 24 DOCK8 patients, 6 (25%) received a matched-related donor transplant, 9 (37.5%) an
unrelated donor transplant, 8 (33.3%) a haploidentical donor transplant, and 1 (4.2%) an
umbilical blood cord.
Twenty-five (65.8%) of the GATA2 patients received a myeloablative conditioning
chemotherapy regimen (these patients were enrolled in second GATA2 protocol), and 13
(34.2%) received a non-myeloablative regimen (these patients were enrolled in the first GATA2
protocol). Twenty-three (95.8%) of the DOCK8 patients received a myeloablative conditioning
regimen, and 1 (4.2%) received a non-myeloablative regimen. Twenty-one (55.3%) of the
GATA2 patients received their HSCT through a graft source of bone marrow, 13 (32.2%)
received peripheral blood stem cells, and 4 (10.5%) of patients received umbilical cord blood.
Nineteen (79.2%) of the DOCK8 patients received their HSCT through bone marrow, 4 (16.7%)
received peripheral blood cells, and 1 (4.2%) received umbilical cord blood.
The majority of patients for GATA2 and DOCK8 received a full matched (6/6, 8/8, or
10/10, depending on the date of matching for transplant) donor transplant, 60.5% and 66.7%,
respectively. The degree of HLA-matching has improved and become more sophisticated over
the years (especially since 2009, the first HSCT explained in this study), currently HLA typing
on these studies are now being typed at 10 alleles. Many of GATA2 and DOCK8 patients are O+
blood type, 47.4% and 50%, respectively. The GATA2 and DOCK8 donors are most frequently
A+ blood type, at 39.5% and 37.5%, respectively.
Medical History
A majority of GATA2 patients (33, 84.6%) and the DOCK8 patients (21, 87.5%) did not
have a secondary diagnosis (a diagnosis in addition to GATA2/MDS or DOCK8). The mean
yearly age of diagnosis of GATA2 patients was 26.7 (SD=8.6 years). The first 8 GATA2 patients
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transplanted, who were all transplanted prior to 2011, had GATA2 mutation diagnosis confirmed
after HSCT since the GATA2 mutation was only identified in 2011. The average yearly age of
diagnosis for DOCK8 patients was 15.1 (SD=7 years). Prior to transplant, GATA2 and DOCK8
patients had an average of 2.2 (SD=1.2) and 1.8 (SD=0.7) life-threatening infections (over
lifetime), respectively. Prior to HSCT, GATA2 and DOCK8 had 14 patients (35.9%) and 14
(58.3%) with serious lung disease, respectively. Prior to HSCT, 23 (59%) of GATA2 patients
had abnormal bone marrow cytogenetics. All 24 (100%) of DOCK8 patients, had normal bone
marrow cytogenetics. Of the GATA2 patients, 35 (89.7%) had MDS, 1 (2.6%) had AML, 2
(5.1%) had both AML and MDS, and 1 (2.6%) had Chronic Myelomonocytic Leukemia
(CMML)/AML and MDS.
Correlations
We explored the relationships between demographic and clinical variables with the
selected outcome variables. Table 10, Bi-variate Correlations between Demographic and
Clinical Variables with Outcomes Among GATA2 Patients who Underwent HSCT summarized
the results for GATA2 patients; and Table 11, Bi-variate Correlations between Demographic and
Clinical Variables with Outcomes Among DOCK8 Patients who Underwent HSCT summarized
the results of DOCK8 patients. The survival rates for GATA2 patients based on donor types: all
6 (100%) patients that received a matched-related donor, 12 (70.6%) patients that received an
unrelated donor, 9 (90%) patients that received a haploidentical donor, and 1 (25%) patient that
received an umbilical cord blood transplant. The following are survival rates for DOCK8 patients
based on survival rates: all 6 (100%) patients that received a matched-related donor, 7 (77.8%)
patients that received an unrelated donor, and 6 (75%) patients that received a haploidentical
donor. For the GATA2 patients, 20 (83.3%) patients who received a myeloablative
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chemotherapy conditioning regimen are alive, and 8 (61.5%) patients that received a nonmyeloablative chemotherapy conditioning regimen are alive. For the DOCK8 patients, 19
(82.6%) patients who received a myeloablative chemotherapy conditioning regimen are alive.
For the GATA2 patients, 12 (80%) of male patients, and 16 (72.7%) female patients are alive.
For the DOCK8 patients, 9 (90%) of male patients, and 10 (71.4%) female patients are alive.
None of the relationships were statistically significant (see Tables 10 and 11). Figure 4, KaplanMeier Curve of GATA2 Survival by Donor and Figure 5, Kaplan-Meier Curve: DOCK8 Survival
by Donor reported the exploratory results. The data is also summarized in Figure 6 Result Bar
Graphs, Pie Charts & Line Charts.
Discussion
Due to the limited number of patients, and the lack of control patients due to the ethical
considerations, there were not enough data (statistical power) to determine the significances of
the variables. Therefore, the research question(s) about the relationships among study variables
could not be definitely answered. However, the valuable data collected in this study is a resource
that can be used for providers to treat other PID patients undergoing HSCT. Due to the limited
sample size, many of the patient characteristics and HSCT variables that predict outcomes in
these two diseases following HSCT remain difficult given the spectrum of patient variables.
However, in describing these variables and exploring their relationships with the overall and
disease-free survival, GVHD, and complications in patients undergoing HSCT, this study
provides valuable information on the characteristics of these patients, although limited numbers
for statistical purposes.
This study provides data for the one-year survival rates of the GATA2 and DOCK8
HSCT patients which were 75.7% and 79.2%, respectively. This information is important as
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when health care providers provide pre-HSCT consultation to patients, they can give reasonable
expectations to patients and families, of an estimation of the survival outcomes. All of the
patients living at one year had a complete response. Given the morbidity and mortality of these
deadly diseases, and that HSCT has been the only proven cure, the data confirms that transplant
represents a beneficial and therapeutic treatment. Data from this study can be used to provide
support and help to oncology nurses and providers caring for these patients to identify factors
before and after HSCT, and to serve a guide for educational needs of GATA2 and DOCK8
HSCT patients. Additionally, providers can assist in determining risk factors for family
members, anticipate needs, and assist in facilitate genetic counseling/testing.
For the living patients, the mean time post-transplant was 46 months (SD=27.7 months)
after HSCT. Nine (24.3%) of the GATA2 patients died (two from sepsis, one from GVHD, three
from graft failure, one from donor cell leukemia, one from cardiac arrest, and one from
malignant disease). For the patients that died, the mean time of death was 349 days (SD=356
days) after HSCT. Nineteen (79.2%) of the 24 DOCK8 patients were alive. For the surviving
patients, the mean time post-transplant was 38 months (SD=16.6 months) after HSCT. Five
(20.8%) of the patients died (two from infection/graft failure, two from GVHD/graft failure, and
one from an illicit drug overdose). For the patients that died, the mean time of death was 246
days (SD=342.3 days) after HSCT.
These patients live with infections, recurrent health problems and serious life-threatening
illness, that often reoccur, or will not respond to therapy. Pre-HSCT, GATA2 deficiency patients
had an average lifetime history of 2.2 life-threatening infections. At one-year post-HSCT, they
experienced an average of 0.8 life-threatening infections. For DOCK8 patients, had an average
lifetime history of 1.79 (SD=0.7) life-threatening infections, and at one-year post-HSCT, they
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experienced an average of 0.9 life-threatening infections. This data indicate that more strategies
need to be developed to prevent infections and treatment among these patients.
Lessons Learned
NIH Investigators have continued to improve transplant protocol preparative regimens,
donor selection, timing for transplant, GVHD regimens, and post-transplant therapies. The first
GATA2 protocol (09-C-0096) used a non-myeloablative chemotherapy conditioning regimen,
the second (13-C-0132) protocol uses a myeloablative chemotherapy conditioning regimen. This
change in chemotherapy conditioning regimen was based from lessons learned from patients on
the first GATA2 protocol. For both GATA2 and DOCK8 protocols, the use of umbilical cord
donors has been eliminated from the protocols. Umbilical cord blood has been replaced by the
use of haploidentical related donors with a marked improvement in outcome. The
implementation of post-transplant cyclophosphamide for GVHD prophylaxis in matched related
and unrelated donors has also resulted in a marked decrease in acute GVHD and chronic GVHD
in these patient populations. All of these improvements indicate that future treatments for these
patients will improve overall survival and quality of life.
Study Limitations
The biggest limitation of this study was the low number of patients and the variability of
the diseases. Both GATA2 and DOCK8 deficiency, although well represented in the NIH study
population, remain rare diseases, with a limited number of patients having undergone HSCT. As
a result, it is difficult to generalize the results to a larger population. There were some patients
who died before one-year post transplant, therefore some dependent variables (outcomes) on
those patients could not be analyzed. GATA2 and DOCK8 deficiency are two very different
clinical PID, with a range of different biochemical defects. The diseases have multiple mutations
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and the expression of the diseases is variable, probably due to difference in the genetic
background of these patients. Therefore, the data from each group when combined is difficult to
analyze together. Although both diseases result in defects in the immune system, the molecular
basis of the defects are different and although the treatment are the same, the heterogeneity of the
patients and spectrum of diseases make correlation in the data difficult and cannot be combined.
Implications/Recommendations for Practice, Policy, and Research
This study fills a gap in the literature and provides information of patient characteristics,
HSCT factors, and the clinical outcomes in GATA2 and DOCK8 deficiency patients who have
undergone HSCT. This project was guided by the World Health Organization’s Social
Determinants of Health theory about the influence of social al factors on health care inequities
and outcomes. Observations showed that GATA2 and DOCK8 patients undergoing HSCT prior
to the development of life-threatening infections, myeloid transformation, or unfavorable
cytogenetic abnormalities appear to have improved clinical outcomes compared to patients
already harboring these signs of clinical progression. However, further studies need to be
conducted to provide additional data to confirm these results.
The results from this study can guide nurses develop better nursing care plans for
GATA2 and DOCK8 patients who undergo HSCT. Oncology nurses are in the primary position
to educate patients and their family members. Working with patients prior to transplant to assure
they have adequate access to local care, post-transplant complication education, and a caregiver
is essential. Prevention of infections, medication compliance, and early recognition of posttransplant complications (GVHD) are important.
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Conclusions

GATA2 and DOCK8 deficiencies are two recently described genetic immunodeficiency
diseases for which allogeneic HSCT represents the only definitive therapy. The sample size of
this project was small (GATA2, n=39 and DOCK8, n=24), and this small sample size limits the
statistical power to examine the effects of some of the variables. Data from this study provides
support and help to oncology nurses caring for these patients to identify prognostic factors for
HSCT, determine risk factors for family members, and note related social determinants. An
important conclusion is the information in this study can help nurses develop better nursing care
plans for GATA2 and DOCK8 patients who undergo HSCT.
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Table 1. Study Variables (Outcome Measure of Interest)- Medical Outcomes.
Variable
Name

Variable
Form

Theoretical Definition

Operational Definition
(SPSS Values)

Engraftment

Binary

Disease-free survival

Chimerism at one-year
post
• Whole blood
• CD3
• Myeloid

Interval
count

Percentage of donor
compared to recipient
graft

1= Yes
2= No
98=Removed from protocol
prior to transplant
99= Not Applicable (NA)
100=Unknown
Chimerism: % (1100)
998=Removed from protocol
prior to transplant
999=NA (dead by one year)
1000=Unknown

Type of response at
one-year post

Binary

Disease status
(Indicates deletion of
phenotype posttransplant)

Life-threatening
infections

Interval
count

Life-infections can be a
post-transplant
complications

Acute graft versus host Categorical Acute GVHD is a postdisease (GVHD)
transplant outcome that
can affect specific
• Skin
organs
• Gastrointestinal
(GI)
• Liver

Chronic GVHD
• Skin
• GI
• Liver
• Mouth
• Eyes
• Lungs
• Genitourinary
(GU)

Categorical Chronic GVHD is a
post-transplant outcome
that can affect specific
organs

Type of response:
1=Complete Response
98=Removed from protocol
prior to transplant
99= NA (dead by one year)
100=Unknown
Number: 110
98=Removed from protocol
prior to transplant
99=NA
100=Unknown
1=Yes
2=No
98=Removed from protocol
prior to transplant
99=NA
100= Unknown

1=Yes
2=No
98=Removed from protocol
prior to transplant
99=NA
100= Unknown

TRANSPLANTATION
Variable
Name
•

41
Variable
Form

Theoretical Definition

Operational Definition
(SPSS Values)

Joints/Fascia

Patient status

Categorical Status post-transplant

Immunosuppression at
one-year post

Categorical Status of
immunosuppression
medication at one year

Death

Clinical

Most severe
complication posttransplant can be death

Interval
count

Days of death posttransplant

Interval
Count

Months post-transplant

Time post-transplant

1= Alive
2=Dead
98=Removed from protocol
prior to transplant
100=Unknown
1= Yes
2= No
98=Removed from protocol
prior to transplant
99=NA (died before one
year post)
100=Unknown
0=Alive
1=Sepsis
2=GVHD
3=Graft failure
4=Donor cell leukemia
5=Cardiac arrest
6=Malignant disease
7=Infection & graft failure
8=GVHD & respiratory
failure
9=Drug Overdose
9998=Removed from
protocol prior to transplant
10000=Unknown
Number of days death posttransplant
9998=Removed from
protocol prior to transplant
9999=NA (alive)
10000=Unknown
Number of months posttransplant
9998=Removed from
protocol prior to transplant
9999=NA (dead)
10000=Unknown
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Table 2. Demographic and Clinical Variables- Demographics.
Variable
Name

Variable
Form

Theoretical Definition

Operational Definition
(SPSS Values)

Insurance status

Binary

Caregiver status

Binary

1=Yes
2=No
1=Yes
2=No

Gender

Binary

Status of patient
insurance coverage
Patients are required to
have a medical
caregiver
Patient’s gender

Occupation/employment

Categorical

Immigration status

Binary

Baseline performance
status

Interval
count

Race

Categorical

Ethnicity

Binary

Marital status

Categorical

Drug history (illicit)

Binary

Access to health care

Binary

1=Male
2=Female
Status of
1=Student
employment/occupation 2=Employed
3=Disabled
4=Unemployed
5=Homemaker
Documentation of
1=US
patient’s immigration
2=Non-US
status
Patient’s performance
Adult scale:
status to assess daily
Karnofsky score: 0100
living abilities and
Pediatric scale (patient’s
functions, based on
under 16-years-old):
provider’s assessment
Lansky: 0100
Patient’s race
1=White,
2=Black/African
American
3=Asian
5=Indian/Alaska Native
100= Unknown
Patient’s ethnicity
1= Not Hispanic or Latino
2= Hispanic or Latino
Patient’s marital status 1=Single
2=Married
3=Divorced
Patients past history of 1=Yes
smoking, alcohol
2=No
and/or drug abuse
Establishment of
1=Yes
home/local primary
2=No
care provider
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Table 3. Demographic and Clinical Variables- Transplant Characteristics.
Variable
Name

Variable
Form

Theoretical
Definition

Cell source

Categorical Cells for transplant
from a donor can be
collected from two
different sources

Conditioning
regimen

Binary

Donor’s gender

Categorical Donor’s gender

Donor age

Interval
count

Transplant type

Categorical Different source of
donor can be
available for
transplant

Graft match

Categorical Degree of human
leukocyte antigen
(HLA) match

Blood type

Categorical Donor and recipient
have different blood
type

Conditioning regimen
given prior to
transplant

Donor age at the time
of transplant

Operational Definition
(SPSS Values)
1=Bone Marrow Transplant
(BMT)
2=Peripheral Blood Stem Cell
(PBSC)
3=Cord
98=Removed from protocol prior
to transplant
1=Myeloablative
2=Non-myeloablative
98=Removed from protocol prior
to transplant
1=Male
2=Female
4=Male, Female
98=Removed from protocol prior
to transplant
Age: 370
98=Removed from protocol prior
to transplant
101=Cord
1=Matched-related donor (MRD)
2= Unrelated donor (URD)
3=Haploidentical (haplo) donor
4=Cord
98=Removed from protocol prior
to transplant
1=Full Match (10/10, 8/8, 6/6)
2=Mismatch (9/10, 8/10)
3=Haplo (5/10, 6/10, 7/10)
4= Double Cord
5= Single Cord
98=Removed from protocol prior
to transplant
Recipient:
1=A+
2=A3=B+
5=O+
6=O8=AB-
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Theoretical
Definition

Operational Definition
(SPSS Values)
98=Removed from protocol prior
to transplant

Viral status

Categorical Recipient and donor
blood viral status are
tested prior to
transplant

Donor:
1=A+
2=A3=B+
5=O+
6=O7=AB+
8=AB9=A+, A+
10=AB+, B+
11=A-, B+
12=O+, O+
13=O+, B+
98=Removed from protocol prior
to transplant
Recipient:
Cytomegalovirus (CMV):
1= Positive
2=Negative
98=Removed from protocol prior
to transplant
100=Unknown
Recipient:
Epstein-Barr virus (EBV):
1= Positive
2=Negative
98=Removed from protocol prior
to transplant
Donor: CMV:
1= Positive
2=Negative
4=Negative, Positive
98=Removed from protocol prior
to transplant
Donor: EBV:
1= Positive
2=Negative
98=Removed from protocol prior
to transplant
100=Unknown
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Table 4. Demographic and Clinical Variables- Medical History.
Variable
Name

Variable
Form

Theoretical
Definition

Operational Definition
(SPSS Values)

Diagnosis

Categorical

Diagnosis of
indication for
transplant

Protocol identified

Binary

Protocol

1=DOCK8
2=GATA2
3=MonoMAC Syndrome (with no
mutation identified)
1=GATA2 protocol (09-C-0096 or
13-C-0132)
2=DOCK8 protocol (10-C-0174)

Date of transplant

Interval
count

Date of transplant

Mutation type

Binary

Type of mutation

Mutation identified

Binary

Malignancy/cancer
diagnosis

Clinical

Mutation
identified by
laboratory
methods
Name of cancer
diagnosis or
malignant disease

Age of diagnosis

Interval
count

Baseline
cytogenetics

Binary

Age at the time of
transplant

Interval
count

Familiar
component

Categorical

Age at the time of
diagnosis
(GATA2 or
DOCK)
Baseline bone
marrow
cytogenetics
Age at the time of
HSCT
Familiar
component of
disease

Date
98=Removed from protocol prior to
transplant
1= Compound heterozygous
2=Homozygous
99= Not applicable (GATA2)
1=Yes
2=No

0= None
1= Emberger syndrome
2=Adenosine deaminase 2 (ADA2)
deficiency
3= EBV driven diseases (EBVdriven T-cell lymphoma, EBVassociated smooth muscle
neoplasm, EBV lymphoma)
5=Burkitt’s lymphoma
6= Hodgkin’s lymphoma
Age (070)
99=NA
100=Unknown
1=Normal
2=Abnormal
Age (070)
98=Removed from protocol prior to
transplant
1=Yes
2=No
100=Unknown
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Variable
Name

Variable
Form

Theoretical
Definition

Operational Definition
(SPSS Values)

Pre-life-threatening
infection history
(life-time)
Serious lung
disease

Interval
count

Number (010)

Hematological
diagnosis

Categorical

Number of life
threatening
infections
Presences of
serious lung
disease at baseline
Diagnosis of
Hematological
Disorder

Induction
chemotherapy

Categorical

Bone Marrow Blast

Categorical

Binary

Induction
cycles/rounds
chemotherapy
given prior to
conditioning
chemotherapy
Number of blast in
the bone marrow
biopsy sample
prior to transplant

1=Yes
2=No
1= Myelodysplastic Syndrome
(MDS)
2=Acute Myeloid Leukemia
(AML)
3=MDS, and AML
4=MDS, AML, and
Chronic Myelomonocytic
Leukemia (CMML)
99= NA (DOCK8)
0= No chemotherapy
1=1 cycle
2=2 cycle
3=3 cycle
99= NA (DOCK8)
0= <5%
1=5-10%
2=11-15%
3=16-20%
4=21-50%
5=51-75%
6=>75%
99=NA (DOCK8)
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Table 5. GANTT Table.

Task
IRB Approval
Data Extraction and Compilation
Data Validation
Data Analysis
Data Write Up

End/Completion
Start Date
Date
5/15/17
9/8/17
9/8/17
11/1/17
1/4/18
1/4/18

1/4/18
1/4/18
3/1/18
3/1/18

Duration
(# of Days)
116
118
64
56
73
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Table 6. Descriptive Tables: Medical Outcomes.
Engraftment
• Yes
• No
Chimerism at one year
• Whole blood
• CD3
• Myeloid
Immunosuppression at one year
• Yes
• No
Response at one year
• Complete response
Acute GVHD (aGVHD)
• Skin aGVHD
o Yes
o No
• GI aGVHD
o Yes
o No
• Liver aGVHD
o Yes
o No
Chronic GVHD (cGVHD)
• Skin cGVHD
o Yes
o No
• GI cGVHD
o Yes
o No
• Liver cGVHD
o Yes
o No
• Mouth cGVHD
o Yes
o No
• Eyes cGVHD
o Yes
o No
• Lungs cGVHD
o Yes
o No

GATA2 (n=35)
33 (94.3%)
2 (5.7%)
GATA2 (n=30)
97.9% (SD-8)
94.0% (SD- 12.8)
98.7% (SD- 6.9)
GATA2 (n=30)
18 (60%)
12 (40%)
GATA2 (n=30)
30 (100%)

DOCK8 (n=24)
22 (91.7%)
2 (8.3%)
DOCK8 (n=20)
99.9% (SD-0.2)
100% (SD-0)
99.9% (SD-0.5)
DOCK8 (n=20)
3 (15%)
17 (85%)
DOCK8 (n=20)
20 (100%)

Total (n=59)
55 (93.2%)
4 (6.8%)
Total (n=50)
98.7 (SD-6.3)
97% (SD-10)
99.2% (SD-5.4)
Total (n=50)
21 (42%)
29 (58%)
Total (n=50)
50 (100%)

GATA2 (n=36)
19 (52.8%)
17 (47.2%)
GATA2 (n=36)
14 (38.9%)
22 (61.1%)
GATA2 (n=36)
5 (13.9%)
31 (86.1%)

DOCK8 (n=24)
16 (66.7%)
8 (33.3)
DOCK8 (n=24)
5 (20.8%)
19 (79.2%)
DOCK8 (n=24)
2 (8.3%)
22 (91.7%)

Total (n=60)
35 (58.3%)
25 (41.7%)
Total (n=60)
19 (31.7%)
41 (68.3%)
Total (n=60)
7 (11.7%)
53 (88.3%)

GATA2 (n=34)
10 (29.4%)
24 (70.6%)
GATA2 (n=34)
6 (17.6%)
28 (82.4%)
GATA2 (n=34)
8 (23.5%)
26 (76.5%)
GATA2 (n=34)
7 (20.6%)
27 (79.4%)
GATA2 (n=34)
15 (44.1%)
19 (55.9%)
GATA2 (n=34)
3 (8.8%)
31 (91.2%)

DOCK8 (n=21)
3 (14.3%)
18 (85.7%)
DOCK8 (n=21)
2 (9.5%)
19 (90.5%)
DOCK8 (n=21)
0 (0%)
21 (100%)
DOCK8 (n=21)
5 (23.8%)
16 (76.2%)
DOCK8 (n=21)
2 (9.5%)
19 (90.5%)
DOCK8 (n=21)
2 (9.5%)
19 (90.5%)

Total (n=55)
13 (23.6%)
42 (76.4%)
Total (n=55)
8 (14.5%)
47 (85.5%)
Total (n=55)
8 (14.5%)
47 (85.5%)
Total (n=55)
12 (21.8%)
43 (78.2%)
Total (n=55)
17 (30.9%)
38 (69.1%)
Total (n=55)
5 (9.1%)
50 (90.9%)
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•

GU cGVHD
o Yes
o No

•

Joints/fascia cGVHD
o Yes
o No

Status
• Alive
• Dead
Number of post life-threatening
infections
• Mean (average)
Months living post
• Mean (average)
Indications of Deaths
• Sepsis
• GVHD
• Graft failure
• Donor cell leukemia
• Cardiac arrest
• Malignant disease
• Infection & graft failure
• GVHD & respiratory
failure
• Drug overdose
Time post death (days)
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GATA2 (n=34)
5 (14.7%)
29 (85.3%)
GATA2 (n=34)
6 (17.6%)
28 (82.4%)
GATA2 (n=37)
28 (75.7%)
9 (24.3%)
GATA2 (n=37)

DOCK8 (n=21)
3 (14.3%)
18 (85.7%)
DOCK8 (n=21)
1 (4.8%)
20 (95.2%)
DOCK8 (n=24)
19 (79.2%)
5 (20.8%)
DOCK8 (n=24)

Total (n=55)
8 (14.5%)
47 (85.5%)
Total (n=55)
7 (12.7%)
48 (87.3%)
Total (n=61)
47 (77.0%)
14 (23.0%)
Total (n=61)

0.76 (SD-1.1)
GATA2 (n=28)
46 (SD-27.7)
GATA2 (n=9)
2 (22.2%)
1 (11.1%)
3 (33.3%)
1 (11.1%)
1 (11.1%)
1 (11.1%)
0 (0%)
0 (0%)

0.92 (SD-0.7)
DOCK8 (n=19)
37.9 (SD-16.6)
DOCK8 (n=5)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
2 (40%)
2 (40%)

0.82 (SD-0.9)
Total (n=47)
42.7 (SD-23.9)
Total (n=14)
2 (14.3%)
1 (7.1%)
3 (21.4%)
1 (7.1%)
1 (7.1%)
1 (7.1%)
2 (14.3%)
2 (14.3%)

0 (0%)
348.6 (SD-356)

1 (20%)
246 (SD-342.3)

1 (7.1%)
311.9 (SD-341.5)
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Table 7. Descriptive Tables: Demographics.
Gender
• Male
• Female
Caregiver status
• Yes
• No
Insurance status
• Yes
• No
Occupation/employment
• Student
• Employed
• Disabled
• Unemployed
• Homemaker
Baseline performance status
Mean Karnofsky/Lansky
Race
• White
•

Black/African American

• Asian
• Indian/Alaska Native
• Unknown
Ethnicity
• Not Hispanic or Latino
• Hispanic or Latino
Marital status
• Single
• Married
• Divorced
Drug history (illicit)
• Yes
• No
Access to health care
• Yes
• No

GATA2 (n=39)
15 (38.5%)
24 (61.5%)
GATA2 (n=39)
37 (94.9%)
2 (5.1%)
GATA2 (n=39)
35 (89.7%)
4 (10.3%)
GATA2 (n=39)
11 (28.2%)
9 (23.1%)
11 (28.2%)
7 (17.9%)
1 (2.6%)
GATA2 (n=39)
65.6 (SD-22.5)
GATA2 (n=39)
31 (79.5%)

DOCK8 (n=24)
10 (41.7%)
14 (58.3%)
DOCK8 (n=24)
24 (100%)
0 (0%)
DOCK8 (n=24)
23 (95.8%)
1 (4.2%)
DOCK8 (n=24)
20 (83.3%)
2 (8.3%)
2 (8.3%)
0 (0%)
0 (0%)
DOCK8 (n=24)
80.4 (SD-15.2)
DOCK8 (n=24)
19 (79.2%)

Total (n=63)
25 (39.7%)
38 (60.3%)
Total (n=63)
61 (96.8%)
2 (3.2%)
Total (n=63)
58 (92.1%)
5 (7.9%)
Total (n=63)
31 (49.2%)
11 (17.5%)
13 (20.6%)
7 (11.1%)
1 (1.6%)
Total (n=63)
71.3 (SD-21.1)
Total (n=63)
50 (79.4%)

1 (2.6%)

0 (0%)

1 (1.6%)

2 (5.1%)
2 (5.1%)
3 (7.7%)
GATA2 (n=39)
30 (76.9%
9 (23.1%)
GATA2 (n=39)
30 (76.9%)
8 (20.5%)
1 (2.6%)
GATA2 (n=39)
2 (5.1%)
37 (94.9%)
GATA2 (n=39)
36 (92.3%)
3 (7.7%)

2 (8.3%)
0 (0%)
3 (12.5%)
DOCK8 (n=24)
20 (83.3%)
4 (16.7%)
DOCK8 (n=24)
23 (95.8%)
0 (0%)
1 (4.2%)
DOCK8 (n=24)
1 (4.2%)
23 (95.8%)
DOCK8 (n=24)
24 (100%)
0 (0%)

4 (6.3%)
2 (3.2%)
6 (9.5%)
Total (n=63)
50 (79.4%)
13 (20.6%)
Total (n=63)
53 (84.1%)
8 (12.7%)
2 (3.2%)
Total (n=63)
3 (4.8%)
60 (95.2%)
Total (n=63)
60 (95.2%)
3 (4.8%)
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Table 8. Descriptive Tables: Transplant Characteristics.
Transplant type
• MRD
• URD
• Haplo
• Cord blood
Conditioning regimen
• Myeloablative
• Non-myeloablative
Donor’s gender
• Male
• Female
• Mixed Donors
(male/ female)
Cell source
• BMT
• PBSC
• Cord
Graft match
• Full Match: (10/10, 8/8,
6/6)
• Mismatch: (8/10, 9/10)
• Haplo match: (5/10, 6/10,
7/10)
• Double cord
• Single cord
Blood type (recipient)
• A+
• A• B+
• O+
• O• ABCMV viral status (recipient)
• Positive
• Negative
• Unknown
EBV viral status (recipient)
• Positive
• Negative

GATA2 (n=38)
6 (15.8%)
18 (47.4%)
10 (26.3%)
4 (10.5%)
GATA2 (n=38)
25 (65.8%)
13 (34.2%
GATA2 (n=38)
18 (47.4%)
19 (50%)
1 (2.6%)

DOCK8 (n=24)
6 (25%)
9 (37.5%)
8 (33.3%)
1 (4.2%)
DOCK8 (n=24)
23 (95.8%)
1 (4.2%)
DOCK8 (n=24)
12 (50%)
11 (45.8%)
1 (4.2%)

Total (n=62)
12 (19.4%)
27 (43.5%)
18 (29%)
5 (8.1%)
Total (n=62)
48 (77.4%)
14 (22.6%)

GATA2 (n=38)
21 (55.3%)
13 (32.2%)
4 (10.5%)
GATA2 (n=38)
23 (60.5%)

DOCK8 (n=24)
19 (79.2%)
4 (16.7%)
1 (4.2%)
DOCK8 (n=24)
16 (66.7%)

Total (n=62)
40 (64.5%)
17 (27.4%)
5 (8.1%)
Total (n=62)
39 (62.9%)

4 (10.5%)
7 (18.4%)

0 (0%)
7 (29.2%)

4 (6.5%)
14 (22.6%)

3 (7.9%)
1 (2.6%)
GATA2 (n=38)
12 (31.6%)
0 (0%)
3 (7.9%)
18 (47.4%)
3 (7.9%)
2 (5.3%)
GATA2 (n=38)
16 (42.1%)
22 (57.9%)
0 (0%)
GATA2 (n=38)
33 (86.8%)
5 (13.2%)

1 (4.2%)
0 (0%)
DOCK8 (n=24)
5 (20.8%)
3 (12.5%)
3 (12.5%)
12 (50%)
1 (4.2%)
0 (0%)
DOCK8 (n=24)
16 (66.7%)
7 (29.2%)
1 (4.2%)
DOCK8 (n=24)
20 (83.3%)
4 (16.7%)

4 (6.5%)
1 (1.6%)
Total (n=62)
17 (27.4%)
3 (4.8%)
6 (9.7%)
30 (48.4)
4 (6.5%)
2 (3.2%)
Total (n=62)
32 (51.6%)
29 (46.8%)
1 (1.6%)
Total (n=62)
53 (85.5%)
9 (14.5%)

30 (48.4%)
30 (48.4%)
2 (3.2%)
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Blood type (donor)
• A+
• A• B+
• O+
• O• AB+
• AB• 2 Donors: (A+ & A+)
• 2 Donors: (AB+ & B+)
• 2 Donors: (A- & B+)
• 2 Donors: (O+ & O+)
• 2 Donors: (O+ & B+)
CMV viral status (donor)
• Positive
• Negative
• 2 donors (mixed):
negative & positive
EBV viral status (donor)
• Positive
• Negative
• Unknown
Donor’s age
• Mean (average)
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GATA2 (n=38)
15 (39.5%)
1 (2.6%)
3 (7.9%)
10 (26.3%)
2 (5.3%)
2 (5.3%)
1 (2.6%)
1 (2.6%)
1 (2.6%)
1 (2.6%)
1 (2.6%)
0 (0%)
GATA2 (n=38)
14 (36.8%)
24 (63.2%)
0 (0%)

DOCK8 (n=24)
9 (37.5%)
2 (8.3%)
2 (8.3%)
7 (29.2%)
2 (8.3%)
0 (0%)
1 (4.2%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (4.2%)
DOCK8 (n=24)
15 (62.5%)
8 (33.3%)
1 (4.2%)

Total (n=62)
24 (38.7%)
3 (4.8%)
5 (8.1%)
17 (27.4%)
4 (6.5%)
2 (3.2%)
2 (3.2%)
1 (1.6%)
1 (1.6%)
1 (1.6%)
1 (1.6%)
1 (1.6%)
Total (n=62)
29 (46.8%)
32 (51.6%)
1 (1.6%)

GATA2 (n=38)
22 (57.9%)
2 (5.3%)
14 (36.8%)
GATA2 (n=35)
33 (SD-14.6)

DOCK8 (n=24)
20 (83.3%)
2 (8.3%)
2(8.3%)
DOCK8 (n=23)
31.3 (SD-13.3)

Total (n=62)
42 (67.7%)
4 (6.5%)
16 (25.8%)
Total (n=58)
32.3 (SD-14)
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Table 9. Descriptive Tables: Medical History.
Diagnosis
• DOCK8
• GATA2
• MonoMAC Syndrome
(with no mutation
identified)
Type of mutation
• Compound heterozygous
• Homozygous
Mutation identified

GATA2 (n=39)
0 (0%)
33 (84.6%)
6 (15.4%)

DOCK8 (n=24)
24 (100%)
0 (0%)
0 (0%)

Total (n=63)
24 (38.1%)
33 (52.4%)
6 (9.5%)

GATA2 (n=0)
*
GATA2 (n=39)

DOCK8 (n=24)
14 (58.3%)
10 (41.7%)
DOCK8 (n=24)

Total (n=63)

• Yes
• No
Malignancy/cancer diagnosis
• None
• Emberger syndrome
• ADA2
• EBV-driven diseases (Tcell lymphoma, EBVassociated smooth muscle
neoplasm, EBV
lymphoma)
• Burkitt’s lymphoma
• Hodgkin’s lymphoma
Age of diagnosis
• Mean (average)
Baseline cytogenetics
• Normal
• Abnormal
Familiar component
• Yes
• No
• Unknown
Pre-life-threatening infections
• Mean (average)
Hematological diagnosis
• MDS only
• AML only
• MDS & AML
• MDS, AML, & CMML

33 (84.6%)
6 (15.4%)
GATA2 (n=39)
33 (84.6%)
3 (7.7%)
1 (2.6%)
2 (5.1%)

24 (100%)
0 (0%)
DOCK8 (n=24)
21 (87.5%)
0 (0%)
0 (0%)
1 (4.2%)

57 (90.5%)
6 (9.5%)
Total (n=63)
54 (85.7%)
3 (4.8%)
1 (1.6%)
3 (4.8%)

0 (0%)
0 (0%)
GATA2 (n=39)
26.7 (SD-8.6)
GATA2 (n=39)
16 (41%)
23 (59%)
GATA2 (n=39)
17 (43.6%)
18 (46.2%)
4 (10.3%)
GATA2 (n=39)
2.18 (SD-1.2)
GATA2 (n=39)
35 (89.7%)
1 (2.6%)
2 (5.1%)
1 (2.6%)

1 (4.2%)
1 (4.2%)
DOCK8 (n=24)
15.1 (SD-5.7)
DOCK8 (n=24)
24 (100%)
0 (0%)
DOCK8 (n=24)
16 (66.7%)
8 (33.3%)
0 (0%)
DOCK8 (n=24)
1.79 (SD-0.7)
DOCK8 (n=0)
**

1 (1.6%)
1 (1.6%)
Total (n=63)
21.8 (SD-9.4)
Total (n=63)
40 (63.5%)
23 (36.5%)
Total (n=63)
33 (52.4%)
26 (41.3%)
4 (6.3%)
Total (n=63)
2.03 (SD-1)
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Serious lung disease (baseline)
• Yes
• No
Induction chemotherapy
• 0 cycle (none)
• 1 cycle
• 2 cycles
• 3 cycles
Bone marrow blasts
• <5%
• 5-10%
• 11-15%
• 16-20%
• 21-50%
• 51-75%
• >75%
Age at time of transplant
• Mean (average)
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GATA2 (n=39)
14 (35.9%)
25 (64.1%)
GATA2 (n=39)
33 (84.6%)
2 (5.1%)
1 (2.6%)
3 (7.7%)
GATA2 (n=39)
34 (87.2%)
1 (2.6%)
1 (2.6%)
0 (0%)
1 (2.6%)
1 (2.6%)
1 (2.6%)
GATA2 (n=38)
27 (SD-7.9)

DOCK8 (n=24)
14 (58.3%)
10 (41.7%)
DOCK8 (n=0)
^

Total (n=63)
28 (44.4%)
35 (55.6%)

DOCK8 (n=0)
^^

DOCK8 (n=24)
17.08 (SD-5.7)

Total (n=62)
23.21 (SD-8.6)

*Type of mutation: Not applicable for GATA2 patients, as GATA2 is an autosomal dominant
genetic disorder
**Hematological Diagnosis: Not applicable for DOCK8 patients, as none of the DOCK8 patients
had a hematological disorder.
^Induction chemotherapy: Not applicable for DOCK8 patients, as none of the DOCK8 patients
required induction chemotherapy, since they did not have any hematological disorders or bone
marrow blast.
^^Bone marrow blast: Not applicable for DOCK8 patients, as none of the DOCK8 patients had
abnormal bone marrows.
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Table 10. Bi-variate Correlations between Demographic and Clinical Variables with
Outcomes Among GATA2 Patients who Underwent HSCT .
Caregiver status
Yes
• Yes
• No
Total

31 (93.9%)
2 (100%)
33 (94.5%)

Drug history (illicit)
• Yes
• No
Total

Engraftment
No

Engraftment
Yes

No

2 (100%)
31 (93.9%)
33 (94.5%)

0 (0%)
2 (6.1%)
2 (5.7%)

Gender
Alive
• Male
• Female
Total

2 (6.1%)
0 (0%)
2 (5.7%)

12 (80%)
16 (72.7%)
28 (75.7%)

Baseline bone marrow
cytogenetics

Alive

• Yes
• No
Total

14 (87.5%)
14 (66.7%)
28 (75.7%)

Transplant type

Status
Dead
3 (20%)
6 (27.3%)
9 (24.3%)
Status
Dead
2 (12.5%)
7 (33.3%)
9 (24.3%)

Total (n=35)
*Fisher’s exact test
(1-sided): p=0.887
2 (5.7%)
33 (94.3%)
35 (100%)
Total (n=37)
*Fisher’s exact test
(1-sided): p=0.456
15 (40.5%)
22 (59.5%)
37 (100%)
Total (n=37)
*Fisher’s exact test (1sided): p=0.141
16 (43.2%)
21 (56.8%)
37 (100%)

•
•
•

MRD
URD
Haplo

6 (100%)
12 (70.6%)
9 (90%)

0 (0%)
5 (29.4%)
1 (10%)

Total (n=37)
*Pearson Chi-Square
(2-sided): p=0.031
6 (16.2%)
17 (45.9%)
10 (27%)

•

Cord

1 (25%)

3 (75%)

4 (10.8%)

28 (75.7%)

9 (24.3%)

37 (100%)

Total

Status

Total (n=35)
*Fisher’s exact test
(1-sided): p=0.887
33 (94.3%)
2 (5.7%)
35 (100%)

Alive

Dead

Insurance status
Alive
• Yes
• No
Total

24 (72.7%)
4 (100%)
28 (75.7%)

Status
Dead
9 (27.3%)
0 (0%)
9 (24.3%)

Total (n=37)
*Fisher’s exact test (1sided): p=0.310
33 (89.2%)
4 (10.8%)
37 (100%)
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Baseline serious lung disease
Alive
• Yes
• No
Total

10 (76.9%)
18 (75%)
28 (75.7%)

Conditioning regimen
Alive
• Myeloablative
• Non-myeloablative
Total

20 (83.3%)
8 (61.5%)
28 (75.7%)

Familiar component

Yes
No

• Unknown
Total

Total

3 (100%)
28 (75.7%)

0 (0%)
9 (24.3%)

3 (8.1%)
37 (100%)

12 (92.3%)
16 (66.7%)

1 (7.7%)
8 (33.3%)

28 (75.7%)

9 (24.3%)

37 (100%)

• Unknown
Total

Status
Dead

18 (85.7%)
2 (100%)

3 (14.3%)
0 (0%)

Total (n=37)
*Pearson Chi-Square (2sided): p=0.111
21 (56.8%)
2 (5.4%)

8 (57.1%)
28 (75.7%)

6 (42.9%)
9 (24.3%)

14 (37.8%)
37 (100%)

Alive
Positive
Negative

Status
Dead

Total (n=37)
*Fisher’s exact test (1sided): p=0.087
13 (35.1%)
24 (64.9%)

Donor’s EBV status
•
•

4 (16.7 %)
5 (38.5%)
9 (24.3%)

Total (n=37)
*Fisher’s exact test (1sided): p=0.142
24 (64.9%)
13 (35.1%)
37 (100%)

4 (23.5%)
5 (29.4%)

Alive
Positive
Negative

Status
Dead

13 (76.5%)
12 (70.6%)

Donor’s CMV status
•
•

3 (23.1%)
6 (25%)
9 (24.3%)

Total (n=37)
*Fisher’s exact test (1sided): p=0.614
13 (35.1%)
24 (64.9%)
37 (100%)

Total (n=37)
*Pearson Chi-Square (2sided): p=0.546
17 (45.9%)
17 (45.9%)

Alive
•
•

Status
Dead

Status
Dead
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Table 11. Bi-variate Correlations between Demographic and Clinical Variables with
Outcomes Among DOCK8 Patients who Underwent HSCT .
Caregiver status

22 (91.7%)

2 (8.3%)

Total (=24) *No
statistics are computed
because caregiver
status is constant.
24 (100%)

0 (0%)
22 (91.7%)

0 (0%)
2 (8.3%)

0 (0%)
24 (100%)

Yes
•

Yes

• No
Total
Drug history (illicit)

Yes
• Yes
• No
Total

Engraftment
No

Engraftment
No

1 (100%)
21 (91.3%)
22 (91.7%)

Gender
Alive
• Male
• Female
Total

9 (90%)
10 (71.4 %)
19 (79.2%)

Baseline bone marrow
cytogenetics

Alive

• Yes
• No
Total

19 (79.2%)
0 (0%)
19 (79.2%)

Transplant type

0 (0%)
2 (8.7%)
2 (8.3%)
Status
Dead
1 (10%)
4 (28.6%)
5 (20.8%)
Status
Dead

5 (20.8%)
0 (0%)
5 (20.8%)

Total (n=24) *Fisher’s
exact test (1-sided):
p=0.283
10 (41.7%)
14 (58.3%)
24 (100%)
Total (n=24) *No
statistics are computed
because baseline bone
marrow cytogenetics is
constant.
24 (100%)
0 (0%)
24 (100%)

•
•
•

MRD
URD
Haplo

6 (100%)
7 (77.8%)
6 (75%)

0 (0%)
2 (22.2%)
2 (25%)

Total (n=24)
*Pearson Chi-Square
(2-sided): p=0.140
6 (25%)
9 (37.5%)
8 (33.3%)

•

Cord

0 (0%)

1 (100%)

1 (4.2%)

19 (79.2%)

5 (20.8%)

24 (100%)

Total

Status

Total (n=24) *Fisher’s
exact test (1-sided):
p=0.917
1 (4.2%)
23 (95.8%)
24 (100%)

Alive

Dead

Baseline serious lung disease
Alive

Status
Dead

Total (n=24)
*Fisher’s exact test
(1-sided): p=0.668
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Total
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11 (78.6%)
8 (80%)
19 (79.2%)

Conditioning regimen
Alive
• Myeloablative
• Non-myeloablative
Total

19 (82.6%)
0 (0%)
19 (79.2%)

Insurance status
Alive
• Yes
• No
Total

18 (78.3%)
1 (100%)
19 (79.2%)

Familiar component

Yes
No

Total

Status
Dead
4 (17.4 %)
1 (100%)
5 (20.8%)
Status
Dead
5 (21.7%)
0 (0%)
5 (20.8%)

Total (n=24)
*Fisher’s exact test
(1-sided): p=0.208
23 (95.8%)
1 (4.2 %)
24 (100%)
Total (n=24)
*Fisher’s exact test
(1-sided): p=0.79
23 (95.8%)
1 (4.2%)
24 (100%)

14 (87.5%)
5 (62.5%)

2 (12.5%)
3 (37.5%)

19 (79.2%)

5 (20.8%)

24 (100%)

Donor’s CMV status

Status
Dead

14 (58.3%)
10 (41.7%)
24 (100%)

Total (n=24)
*Fisher’s exact test
(1-sided): p=0.189
16 (66.7%)
8 (33.3%)

Alive
•
•

3 (21.4%)
2 (20%)
5 (20.8%)

•
•

Positive
Negative

11 (73.3%)
8 (100%)

4 (26.7%)
0 (0%)

Total (n=24)
*Pearson Chi-Square
(2-sided): p=0.045
15 (62.5%)
8 (33.3%)

•

Negative, Positive

0 (0%)

1 (100%)

1 (4.2%)

19 (79.2%)

5 (20.8%)

24 (100%)

Alive

Total
Donor’s EBV status

•
•

Positive
Negative

• Unknown
Total

Status
Dead

Status

Total (n=24) *Pearson
Chi-Square (2-sided):
p=0.014

Alive

Dead

17 (85.0%)
2 (100 %)

3 (15%)
0 (0%)

20 (83.3%)
2 (8.3%)

0 (0%)
19 (79.2%)

2 (100%)
5 (20.8%)

2 (8.3%)
24 (100%)
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Figure 1. Clinical Features of GATA2.

Adapted from: (Spinner et al., 2014)
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Figure 2. Clinical Features of DOCK8.

(Cuellar-Rodriguez et al., 2015).
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Figure 3. Theoretical Framework.

Adapted from World Health Organization, 2010.
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Figure 4. Kaplan-Meier Curve: GATA2 Survival by Donor.

MRD-Matched-relelated Donor
Haplo-Haploidentical Donor
URD-Unreleated Donor
Cord-Umbilical Cord Blood
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Figure 5. Kaplan-Meier Curve: DOCK8 Survival by Donor.
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Figure 6 Result Bar Graphs, Pie Charts & Line Charts.

Patient Status

Engraftment

64

TRANSPLANTATION

Life-threating Infections

Graft Source

GATA2 (n=38) DOCK8 (n=24)
BMT-Bone Marrow Transplant
PBSC-Peripheral Blood Stem Cells
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Donor’s Age and Recipient Age at the Time of Transplant

Donor: GATA2 (n=35), DOCK8 (n=23) Cord Donor Age: NA
Patient/Recipient: GATA2 (n=38), DOCK8 (n=24)

GATA2: Performance Score and Age of Transplant

GATA2 (n=38) Arranged in enrollment order
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GATA2: Hematological Diagnosis

GATA2 (n=39)

GATA2: Baseline Cytogenetics

GATA2 (n=39)
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